Guo's Visceral Arteries Reconstruction: First in Man Study

Inclusion Criteria: 1. Age ≥18 and ≤80 years; 2. Patients diagnosed with type Crawford I-V thoracoabdominal aortic aneurysmsa and pararenal abdominal aortic aneurysm, and should meet at least one of the following conditions: 1. The maximum diameter of thoracoabdominal aortic aneurysms and pararenal abdorminal aortic aneurysm \> 50 mm; 2. Rapid growth of sac \>5 mm in diameter in the most recent 6 months; 3. Definite symptoms of abdominal pain and low back pain associated with thoracicabdominal aortic aneurysms. 3. Patients with four indispensable reno-visceral arteries including superior mesenteric artery, celiac trunk and bilaterial renal arteries. 4. Proximal landing zone 20-36 mm in diameter; 5. Proximal landing zone ≥25 mm in length; 6. If distal landing zone in abdominal aorta, distal landing zone should be 12-36mm in diameter and ≥15 mm in length. 7. The visceral vascular branches landing zone 6\~13 mm in diameter and ≥15 mm in length; 8. The renal artery landing zone 4.5\~9 mm in diameter and ≥15 mm in length; 9. Patients who using the abdominal aortic bifurcation stent graft system should also meet the following criteria: 1. The ilac artery landing zone 7 \~25 mm in diameter; 2. The ilac artery landing zone ≥15 mm in length; 10. Patients with appropriate iliacofemoral access and at least one patent upper extremity access; 11. Patients who can understand the purpose of the trial, volunntarily participate and sign the informed consent form, and are willing to complete the follow-up according to the requirements of the protocol; Exclusion Criteria: 1. Ruptured aortic aneurysm in unstable haemodynamic condition; 2. Aneurysmal aortic dissection; 3. Infected or mycotic aortic aneurysm; 4. Requiring simultaneous coverage or embolisation for bilateral internal iliac arteries; 5. Severe stenosis, calcification, or mural thrombus at stent-graft landing zone; 6. Diagnosis of acute coronary syndrome within 6 months; 7. Patients with any transient ischemic attack (TIA) or ischemic stroke within 3 months; 8. An allergic history for contrast agents, anticoagulants, antiplatelet drugs, stent graft or materials of delivery system； 9. Patients with connective tissue diseases; 10. Patients with takayasu arteritis; 11. Patients with serious vital organ dysfunction or other serious disease; 12. Preoperative liver renal function abnormalities (ALT or AST ≥ 5 times the upper limit of normal value), or serum creatinine ≥ 150 μmol/L; 13. Severe pulmonary insufficiency who cannot tolerate general anaesthesia; 14. Severe coagulation dysfunction; 15. Undergone major surgical or interventionic surgery within 30 days before surgery; 16. Patients whose systemic or local infection may increase the risk of intravascular graft infection; 17. Planning pregnancy, pregnancy, or breastfeeding; 18. The patient participated in other clinical trials or not completed or withdrawn from other clinical trials within the last 3 months at the time of screening period ; 19. Life expectancy less than 1 year; 20. Patients not appropriate for endovascular repair based on the investigators' clinical judgement.